Rationale for MEK/BRAF Combinations in Melanoma
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib with trametinib or binimetinib with encorafenib for patients with melanoma.<br />
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses the rationale for combining agents like dabrafenib (Tafinlar) with trametinib (Mekinist) or binimetinib (Mektovi) with encorafenib (Braftovi) for patients with melanoma.
We’ve known for a number of years that mutatedBRAFis a bonafide therapeutic target for this patient population, Flaherty explains. Approximately 45% of patients with melanoma have activating mutations in BRAF. Around 2009, vemurafenib (Zelboraf) and dabrafenib came along and proved thatBRAFmutations were therapeutic targets. Within a few years, these drugs were FDA-approved for this patient population.
Advancing Neoadjuvant Therapy for HER2+ Breast Cancer Through ctDNA Monitoring
December 19th 2024In an interview with Targeted Oncology, Adrienne Waks, MD, provided insights into the significance of the findings from the DAPHNe trial and their clinical implications for patients with HER2-positive breast cancer.
Read More
AI-Driven Deep Learning Model Shows Promise in Standardizing MDS Diagnosis
December 10th 2024In an interview, Palak Dave discussed how artificial intelligence, using deep learning to analyze bone marrow aspirate smear images, could standardize and accelerate the diagnosis of MDS vs pre-MDS conditions.
Read More
Systemic Therapy Choice Linked to Radiosurgery Outcomes in Brain Mets
December 6th 2024In an interview with Targeted OncologyT, Rupesh Kotecha, MD, discussed a study focused on how systemic therapy selection impacts outcomes in patients with brain metastases, particularly those with lung cancer.
Read More
